Allspring Global Investments Holdings LLC Reduces Stake in LivaNova PLC $LIVN
Allspring Global Investments Holdings LLC reduced its stake in LivaNova PLC (LIVN) by 8.9% in Q4 2026, selling 19,629 shares and now owning 201,832 shares valued at $12.42 million. Despite this reduction, other institutional investors have increased their holdings, and LivaNova reported strong Q4 earnings, beating expectations with $0.86 EPS and revenue of $360.92 million. The stock holds a "Moderate Buy" consensus rating with an average price target of $74.78.
Exchange Traded Concepts LLC Buys New Shares in LivaNova PLC $LIVN
Exchange Traded Concepts LLC recently acquired 15,768 shares of LivaNova PLC, valued at approximately $970,000, during the fourth quarter. This acquisition is part of a trend where institutional investors now own 97.64% of the company's stock. LivaNova PLC exceeded its Q4 earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from analysts with an average target price of $74.78.
(LIVN) Movement Within Algorithmic Entry Frameworks
Livanova Plc (NASDAQ: LIVN) shows weak near-term sentiment while maintaining long-term strength, with no clear price positioning identified and elevated downside risk. Algorithmic models provide three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. Multi-timeframe analysis reveals divergent sentiment, suggesting choppy conditions with weak near-term and strong long-term signals.
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC $LIVN
Tudor Investment Corp ET AL recently acquired a new stake of 33,332 shares in LivaNova PLC (LIVN) during the third quarter, valued at approximately $1.75 million. Institutional ownership of LivaNova is high at 97.64%, with other firms like Parkman Healthcare Partners LLC also significantly increasing their holdings. LivaNova reported strong Q3 earnings, beating analyst estimates, and provided positive FY2026 guidance, leading to a "Moderate Buy" consensus rating among analysts with an average price target of $74.78.
Tudor Investment Corp ET AL Acquires Shares of 33,332 LivaNova PLC
Tudor Investment Corp ET AL has acquired a new stake of 33,332 shares in LivaNova PLC for approximately $1.75 million, representing 0.06% ownership. This investment signals the hedge fund's confidence in LivaNova's growth potential and its innovative cardiac and neuromodulation solutions. The acquisition highlights the continued interest from institutional investors in the medical technology sector.
How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors
The FDA's premarket approval of LivaNova's aura6000 System for obstructive sleep apnea is expected to significantly impact the company's investment narrative, strengthening its neuromodulation portfolio. While this approval offers a new growth driver, investors should also consider the potential risks associated with slower commercialization or higher-than-expected launch costs, which could affect the company's ability to meet its 2026 revenue guidance and profitability targets. The article highlights LivaNova's projected revenue of $1.7 billion and earnings of $173.6 million by 2029, suggesting a fair value upside for LIVN stock.
LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Apnea
LivaNova PLC (NASDAQ:LIVN) announced that the FDA has granted premarket approval for its aura6000 System, designed for adults with moderate to severe obstructive sleep apnea who cannot use or respond to other therapies. This approval follows positive Q4 results, with the company reporting adjusted EPS of 86c and revenue of $360.9M. Analysts have raised price targets for LivaNova, citing a strong outlook for 2026.
LivaNova Broadens OSA Treatment Options With FDA Clearance for aura6000 System
LivaNova has received FDA premarket approval for its aura6000 System, a neurostimulation device for adults with moderate to severe Obstructive Sleep Apnea (OSA). This system, employing proximal hypoglossal nerve stimulation (p-HGNS), offers a new treatment option for patients who cannot tolerate or are unsuitable for standard therapies. The approval is based on positive results from the OSPREY clinical trial and is expected to boost LivaNova's market position while providing a promising alternative for OSA patients.
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LivaNova has secured FDA premarket approval for its aura6000 system, an innovative neurostimulation device treating moderate to severe Obstructive Sleep Apnea (OSA) in adults aged 15 to 65. The system uses proximal hypoglossal nerve stimulation (p-HGNS) and is intended for patients who cannot tolerate or respond to first-line treatments. This approval follows strong efficacy and safety data from the OSPREY trial, positioning LivaNova for new revenue growth in the sleep apnea market.
LivaNova to Announce First-Quarter 2026 Results
LivaNova PLC will host a conference call on Wednesday, May 6, 2026, at 1 p.m. London time (8 a.m. EDT) to discuss its first-quarter 2026 financial results. The company plans to release its results prior to the call, which will be accessible via audiocast on its website or by telephone. LivaNova, a global medical technology company, will also make a replay available on its investor relations section.
LivaNova (LIVN) Announces FDA Approval of aura6000 System for Obstructive Sleep Out of breath
LivaNova PLC (NASDAQ:LIVN) announced FDA approval for its aura6000 System, designed to treat moderate to severe obstructive sleep apnea in adults who cannot use or respond to other first-line therapies. This news comes after several analysts raised their price targets on LivaNova following a strong Q4 earnings beat. The company's CEO, Vladimir Makatsaria, highlighted double-digit revenue growth and plans to invest further in its OSA platform.
LivaNova PLC stock faces analyst scrutiny amid mixed ratings and modest growth outlook in medical de
LivaNova PLC (LIVN) is a global medical technology firm specializing in cardiac surgery and neuromodulation, currently trading on NASDAQ with a "moderate buy" consensus from analysts. With an average price target of $59.71, the company is seen as having modest upside despite recent negative EPS, with expectations for future profitability growth. US investors are monitoring its path to profitability, declining short interest, and its positioning in the medical device sector supported by steady demand and expanding indications for its therapies.
LivaNova PLC stock faces analyst scrutiny amid mixed ratings and modest growth outlook in medical de
LivaNova PLC, a global medical technology firm specializing in cardiac surgery and neuromodulation, is under analyst scrutiny with mixed ratings and a modest growth outlook. Despite historical losses, the company shows signs of a profitability turnaround with positive current ratios and declining short interest, appealing to US investors seeking recovery stories in medtech. The company faces competitive pressures and regulatory hurdles but aims for long-term growth through M&A and innovation in underserved healthcare niches.
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Rating of "Moderate Buy" from Brokerages
LivaNova PLC (NASDAQ:LIVN) has received a consensus "Moderate Buy" rating from ten brokerages, with an average 12-month price target of $74.78. The company recently surpassed earnings expectations, reporting $0.86 EPS against an anticipated $0.80, and generated $360.9 million in revenue, up 12.2% year-over-year. LivaNova also issued a strong FY2026 EPS guidance of $4.15-$4.25.
FDA Approves LivaNova’s aura6000 Neurostimulator for OSA
The FDA has approved LivaNova's aura6000 System, a neurostimulator for adults with moderate to severe obstructive sleep apnea (OSA) who cannot use other therapies. This device is notable as the first approved in the US without a complete concentric collapse contraindication or the need for pre-implantation drug-induced sleep endoscopy. Clinical trials demonstrated a 65% responder rate at 12 months, with significant improvements in AHI and ODI.
LivaNova aura6000 Obstructive Sleep Apnea treatment granted FDA premarket approval
LivaNova's aura6000 System, designed for treating moderate to severe Obstructive Sleep Apnea (OSA) using proximal hypoglossal nerve stimulation (p-HGNS), has received premarket approval (PMA) from the FDA. This approval is supported by data from the OSPREY randomized controlled trial, which demonstrated significant reductions in AHI and ODI. LivaNova plans to introduce a next-generation device with MRI compatibility, remote configuration, and an extended battery life.
LivaNova eyes 2027 launch of neural sleep apnoea therapy after FDA approval
LivaNova has received FDA premarket approval for its aura6000 system, a neuromodulation therapy for moderate- to severe obstructive sleep apnea (OSA). The system, which uses hypoglossal nerve stimulation, is anticipated to launch in 2027. This approval is a significant step for LivaNova and offers a new treatment option for OSA patients who cannot use or benefit from traditional CPAP therapy.
LivaNova gains FDA premarket approval for Aura6000 for sleep apnea
The article reports that LivaNova has received FDA premarket approval for its Aura6000 system, a crucial development for the company. While the complete content is not provided, the headline suggests that the device is intended for the treatment of sleep apnea. This approval marks a significant milestone for LivaNova in the medical device market.
LivaNova’s Aura6000 FDA Win Reshapes Obstructive Sleep Apnea Opportunity
LivaNova's Aura6000 system has received FDA premarket approval for treating moderate to severe Obstructive Sleep Apnea, offering a new alternative for patients not benefiting from standard therapies. The company is also developing an MRI-compatible version, indicating continued investment in its OSA platform. This approval moves LivaNova's OSA efforts into the commercial sphere, with implications for patient adoption, reimbursement, and market competition against established players.
How (LIVN) Movements Inform Risk Allocation Models
This article analyzes Livanova Plc (NASDAQ: LIVN), noting a positive near-term sentiment amidst a mid-term weak bias and long-term strength. It highlights an exceptional risk-reward setup targeting a 9.2% gain with minimal risk and outlines three AI-generated trading strategies for different risk profiles. The analysis includes multi-timeframe signal assessments and current support/resistance levels.
LIVN SEC Filings - Livanova Plc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Livanova Plc (LIVN) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights recent filings such as director RSU grants and vesting, board appointments, and a Q2 2025 financial report detailing solid growth despite a significant environmental charge. The platform enhances these filings with AI-powered summaries and real-time updates.
LIVN SEC Filings - Livanova Plc 10-K, 10-Q, 8-K Forms
This page provides access to Livanova Plc's SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events, for investors and traders. It features AI-powered summaries to highlight key information and real-time updates from the EDGAR system. Recent filings detail insider transactions, Q3 2025 financial results, and a new director appointment to the board.
LivaNova granted premarket approval for aura6000 System by FDA
LivaNova (LIVN) has received premarket approval from the FDA for its aura6000 System, designed to treat adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The system uses proximal hypoglossal nerve stimulation and is intended for patients with an apnea-hypopnea index between 15 and 65 who have not responded to or cannot tolerate first-line therapies like positive airway pressure. Analysts have recently raised their price targets for LivaNova following a strong quarter.
LivaNova gains FDA premarket approval for Aura6000 for sleep apnea
LivaNova has received FDA premarket approval for its Aura6000 vagal nerve stimulation (VNS) system, which is indicated for the treatment of moderate-to-severe obstructive sleep apnea. This approval marks a significant step for the company in expanding its VNS therapy into a new therapeutic area, offering a new treatment option for patients with sleep apnea who struggle with traditional therapies like CPAP.
LivaNova (LIVN) Receives FDA Approval for Aura6000 Sleep Apnea System
LivaNova (LIVN) has received FDA approval for its Aura6000 System, a novel neurostimulation device for moderate to severe Obstructive Sleep Apnea. Despite this innovative product and a focus on medical devices, the company faces financial challenges including negative earnings and a distressed Altman Z-Score, indicating potential bankruptcy risk. Investors are advised to monitor product launches and regulatory developments.
LivaNova Earns FDA Approval for Neurostim for Sleep Apnea
LivaNova has received FDA premarket approval for its aura6000 system, a neurostimulation device designed to treat moderate to severe obstructive sleep apnea (OSA). The system uses proximal hypoglossal nerve stimulation (p-HGNS) and is intended for patients who have failed or cannot tolerate other first-line therapies. Clinical trial data showed significant improvement in AHI, demonstrating the therapy's safety and efficacy.
LivaNova wins FDA approval for sleep apnea nerve device
LivaNova PLC announced FDA approval for its aura6000 System, a nerve stimulation device for moderate to severe obstructive sleep apnea. This therapy is notable for not requiring a complete concentric collapse contraindication or pre-implantation drug-induced sleep endoscopy. The company is also developing a next-generation device with enhanced features, expected to launch in mid-2027.
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LivaNova PLC has received U.S. FDA premarket approval for its aura6000™ System, a hypoglossal nerve stimulation therapy for moderate to severe Obstructive Sleep Apnea (OSA). This system is notable as the first and only FDA-approved device of its kind without a complete concentric collapse contraindication, offering an alternative for patients who cannot tolerate or fail first-line therapies like PAP. LivaNova plans to launch a next-generation, MRI-compatible version of the device in the first half of 2027, pending further FDA review.
LivaNova Shares Gain 2% After Strong Q3 Results and Upgraded Full-Year Outlook
LivaNova shares rose by 2% following the announcement of strong Q3 results that surpassed analyst expectations. The company also raised its full-year revenue outlook, indicating continued positive performance. This positive financial news was well-received by the market.
LivaNova PLC announced that its Aura6000 system has received premarket approval from the U.S. Food and Drug Administration (FDA). The device is designed to treat moderate to severe obstructive sleep apnea.
LivaNova PLC has received premarket approval from the U.S. Food and Drug Administration (FDA) for its Aura6000 system. This device is intended for the treatment of moderate to severe obstructive sleep apnea. This regulatory milestone allows LivaNova to market its innovative therapy in the United States.
Short Interest in LivaNova PLC (NASDAQ:LIVN) Rises By 18.0%
Short interest in LivaNova PLC (NASDAQ:LIVN) increased by 18.0% in February, reaching 2,399,324 shares, which now represents 4.4% of the shares shorted and a short-interest ratio of 2.4 days. Despite this rise in bearish positioning, institutional investors hold a significant 97.64% stake, with several major funds recently increasing their positions. Analysts maintain a "Moderate Buy" consensus, with an average target price of $74.78, following the company's recent beat on quarterly EPS and revenue estimates.
Algert Global LLC Cuts Stock Position in LivaNova PLC $LIVN
Algert Global LLC significantly reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 47.4% during the third quarter, selling 145,265 shares and retaining 160,934 shares valued at $8.43 million. Other institutional investors showed mixed activity, with some increasing their positions while funds collectively own 97.64% of the company's stock. Analysts currently hold a "Moderate Buy" consensus rating with a target price of $74.78 for LivaNova.
LivaNova PLC (LIVN) Stock Price Up 4.47% on Mar 16
Shares of LivaNova PLC (LIVN) rose 4.47% on March 16, reaching an intraday high of $61.47 before closing at $61.01. Wall Street analysts have an average target price of $77.76 for LIVN, implying a 27.45% upside, with a consensus "Outperform" rating. GuruFocus estimates a one-year fair value (GF Value) of $65.16, suggesting a 6.8% upside.
Boone Capital Management LLC Purchases Shares of 167,932 LivaNova PLC $LIVN
Boone Capital Management LLC recently purchased 167,932 shares of LivaNova PLC (NASDAQ: LIVN), a medical technology company, valued at approximately $8.8 million in the third quarter. This acquisition represents 2.9% of Boone Capital's portfolio and 0.31% ownership of LivaNova. Other institutional investors like Artisan Partners and Wellington Management Group also significantly increased their stakes, bringing total institutional ownership to 97.64%. The company recently reported strong quarterly earnings, beating EPS expectations with revenue growth, and holds a "Moderate Buy" consensus rating from analysts.
P2 Capital Partners LLC Trims Stock Holdings in LivaNova PLC $LIVN
P2 Capital Partners LLC reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 3.9% in the third quarter, now owning 493,902 shares valued at approximately $25.87 million, making it their 7th largest holding. The medical technology company recently exceeded Q3 earnings and revenue estimates and has a "Moderate Buy" consensus rating from analysts with a target price of $74.78. LivaNova's stock performance and financial metrics, including a market cap of $3.20 billion, are detailed in the article.
LivaNova PLC (NASDAQ:LIVN) Q3 2025 Earnings Call Transcript
This document is an earnings call transcript for LivaNova PLC's Q3 2025 financial results. It indicates that the full transcript is available through MSN, suggesting a detailed discussion of the company's performance, financial figures, and outlook for the quarter.
LivaNova PLC Stock (ISIN: US5356991077) Faces Headwinds Amid Mixed Guidance and Declining Sentiment
LivaNova PLC (ISIN: US5356991077) has seen its stock decline over 8% monthly despite a "Moderate Buy" consensus and recent earnings beats. This downturn is attributed to broader market dynamics, lingering sentiment from an October 2025 downgrade, and a significant net income loss driven by one-off items, despite strong revenue growth and positive 2026 EPS guidance. European investors are closely watching the medtech firm, weighing its diversified segments in cardiac surgery and neuromodulation against current valuation and profitability challenges.
Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)
LivaNova (LIVN) has experienced a 7.2% decline in its stock price over the past four weeks, but indicators suggest it is now oversold and poised for a potential rebound. Its Relative Strength Index (RSI) of 27.99 indicates it's in oversold territory, and a 2.3% increase in consensus EPS estimates by Wall Street analysts over the last 30 days points to improving fundamentals. Furthermore, LIVN holds a Zacks Rank #2 (Buy), reinforcing the expectation of a near-term turnaround.
LivaNova (LIVN) executive exercises SARs, net shares after tax withholding
LivaNova PLC executive Franco Poletti exercised 2,140 Stock Appreciation Rights (SARs), which converted into ordinary shares. After tax withholdings and covering the SAR base price, he netted 91 shares, increasing his direct holdings to 8,941 shares, with an additional 219 shares held indirectly through his spouse. This transaction was a routine, non-discretionary compensation event, not an open-market sale.
Trading Systems Reacting to (LIVN) Volatility
This article analyzes Livanova Plc (LIVN) volatility, identifying weak near-term sentiment despite potential long-term strength. It presents specific institutional trading strategies (Long Position, Momentum Breakout, Risk Hedging) with detailed entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis indicating choppy conditions. The analysis highlights an exceptional 30.1:1 risk-reward setup, targeting an 8.8% gain versus a 0.3% risk.
American Century Companies Inc. Buys 175,570 Shares of LivaNova PLC $LIVN
American Century Companies Inc. significantly increased its stake in LivaNova PLC by acquiring an additional 175,570 shares, bringing its total holdings to 726,950 shares valued at approximately $38.08 million. This move is part of broader institutional interest, with other major hedge funds like Artisan Partners and Invesco also substantially increasing their positions in LivaNova. The company, which is 97.64% institutionally owned, recently beat its quarterly EPS and revenue estimates and holds a "Moderate Buy" analyst rating with an average price target of $74.78.
Vanguard Group Inc. Lowers Holdings in LivaNova PLC $LIVN
Vanguard Group Inc. recently decreased its stake in LivaNova PLC (NASDAQ:LIVN) by 6.4% in the third quarter of 2025, now holding approximately 4.21% of the company's shares. Despite this reduction, analysts maintain a "Moderate Buy" consensus rating for LivaNova, with several firms raising price targets following the company's strong Q4 earnings beat and optimistic FY2026 guidance. LivaNova, a global medical technology company, reported $0.86 EPS and $360.9 million in revenue for the quarter, surpassing analyst expectations.
Rock Point Advisors LLC Makes New Investment in LivaNova PLC $LIVN
Rock Point Advisors LLC initiated a new position in LivaNova PLC (NASDAQ:LIVN) by acquiring 58,535 shares valued at approximately $3.07 million, representing about 0.11% of the company. Other institutional investors like Artisan Partners and Invesco also significantly increased their holdings in LivaNova, bringing overall institutional ownership to 97.64%. LivaNova recently surpassed quarterly EPS estimates and provided FY2026 EPS guidance, holding a consensus "Moderate Buy" rating from analysts with an average price target of $74.78.
LivaNova PLC (NASDAQ:LIVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
LivaNova PLC (NASDAQ:LIVN) has received a consensus "Moderate Buy" recommendation from brokerages, with several analysts raising their price targets after the company's strong Q4 performance. The company exceeded revenue and adjusted EPS expectations and provided optimistic FY2026 adjusted EPS guidance, despite reporting a negative net margin for GAAP earnings. Institutional investors have notably increased their stakes in LivaNova, reflecting growing confidence in the stock.
LivaNova PLC $LIVN Shares Acquired by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. significantly increased its stake in LivaNova PLC (NASDAQ:LIVN) by 168.1% in the third quarter. This comes as LivaNova exceeded Q4 earnings and revenue expectations and provided strong FY2026 guidance. The stock is currently trading near its 52-week high, with institutional investors holding a substantial portion of the company's shares.
LIVN: Barclays Raises Price Target, Maintains Equal-Weight Ratin
Barclays has increased its price target for LivaNova (LIVN) by 8.96% to $73.00, while maintaining an "Equal-Weight" rating. This adjustment follows other recent analyst updates for LivaNova, but the GuruFocus estimated GF Value of $63.39 suggests a potential downside from the current trading price. The article highlights LivaNova's core business in cardiopulmonary solutions and neuromodulation, with significant revenue from the US and Europe.
Needham Maintains Buy on LivaNova PLC (LIVN) Feb 25, 2026 PT Raised to $81
Needham has reaffirmed its Buy rating on LivaNova PLC (LIVN) and increased its price target to $81, signaling continued confidence in the company's growth trajectory. This decision follows LivaNova's strong Q4 2025 results and positive 2026 guidance, which projected 6%–7% revenue growth. The maintained Buy rating with a higher price target suggests that Needham sees potential for increased valuation without altering its risk assessment for the company.
LivaNova (LIVN) Q4 2025 Earnings Call Transcript
LivaNova (LIVN) reported strong Q4 and full-year 2025 results, with double-digit revenue and EPS growth, driven by its Cardiopulmonary and Epilepsy businesses. The company outlined its strategic progress, including entry into high-growth segments like obstructive sleep apnea (OSA) and digital health, and provided positive 2026 guidance, expecting 6%-7% revenue growth and $4.15-$4.25 adjusted diluted EPS. Key drivers for 2026 include continued ESSENCE penetration, market share gains in consumables, and improved VNS Therapy reimbursement for Epilepsy.
LivaNova PLC SEC 10-K Report
LivaNova PLC has released its 2025 10-K report, detailing strong financial growth with net revenue up 10.7% to $1,388.1 million, driven by its Cardiopulmonary and Neuromodulation segments. The report highlights strategic debt reduction, successful new product launches, and ongoing investments in R&D, while also addressing challenges like market competition, cybersecurity threats, and regulatory compliance. The company aims to maintain technological leadership and expand market presence despite a reported net loss of $242.5 million due to an environmental liability.
LivaNova PLC (LIVN) Q4 2025 Earnings Call Highlights: Strong Rev
LivaNova PLC (LIVN) reported strong Q4 2025 earnings, achieving double-digit revenue growth for the fifth consecutive year across both cardiopulmonary and epilepsy segments. Despite facing supply chain constraints and some market challenges, the company showed significant improvement in adjusted operating margins and robust cash generation. LivaNova also provided optimistic guidance for 2026, forecasting continued revenue growth and improved profitability, driven by strategic advancements in high-growth markets and positive clinical outcomes.
